Outcome of Board Meeting

Concord Biotech Limited has submitted its unaudited financial results for the second quarter and half year ended September 30, 2026. The Board of Directors has also approved the reconstitution of various committees, including the Audit Committee, Nomination and Remuneration Committee, Risk Management Committee, and Corporate Social Responsibility Committee. Additionally, the Board has fixed November 4, 2026, as the record date for the issue of bonus equity shares.